AstraZeneca and Bind Therapeutics will collaborate on a targeted, programmable, nanotechnology cancer treatment involving a kinase inhibitor. The nanoparticles, which Bind calls Accurins, selectively accumulate, causing higher drug concentrations at the site of a tumor while sparing healthy tissue. AstraZeneca is also working with Horizon Discovery on a kinase therapy that targets the K-Ras mutation in various cancers, including of the lung and colon.
AstraZeneca collaborates on cancer nanomedicine
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore